Can we Reduce the Number of Vaccine Injections for Children?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

404 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial. Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other concurrent routine vaccinations. All groups will also be further divided into 2 groups to receive their routine vaccines in either consistent or alternating limbs to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24 months of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Understanding the Persistence of Immunity After MenC Vaccines

NCT01126996

Healthy

COMPLETED

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

NCT00262002

Prevention of Meningococcal Disease

COMPLETED PHASE2

Understanding Immunity Persistence After Adolescent MenC Vaccination

NCT01459432

Antibody Persistance After Booster Dose of Men C Vaccine

COMPLETED

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

NCT02919293

Meningitis Meningococcal Meningitis Meningococcal Infections

UNKNOWN PHASE1/PHASE2

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

NCT00311415

Prevention of Meningococcal Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Invasive Meningococcal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Two Dose MenC Group

Two doses of MenC-CRM197 priming at 3 and 4 months of age.

Group Type EXPERIMENTAL

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

Intervention Type BIOLOGICAL

In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.

Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Routine schedule immunisations except monovalent MenC vaccine

Intervention Type BIOLOGICAL

Routine schedule immunisations will be given according to NHS guidelines.

Single Dose MenC-CRM197 Group

One dose of MenC-CRM197 priming at 3 months of age.

Group Type EXPERIMENTAL

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

Intervention Type BIOLOGICAL

In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.

Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Routine schedule immunisations except monovalent MenC vaccine

Intervention Type BIOLOGICAL

Routine schedule immunisations will be given according to NHS guidelines.

Single Dose MenC-TT Group

Single dose MenC-TT priming at 3 months of age

Group Type EXPERIMENTAL

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

Intervention Type BIOLOGICAL

In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.

Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Routine schedule immunisations except monovalent MenC vaccine

Intervention Type BIOLOGICAL

Routine schedule immunisations will be given according to NHS guidelines.

Control Group

Zero dose MenC priming

Group Type EXPERIMENTAL

Routine schedule immunisations except monovalent MenC vaccine

Intervention Type BIOLOGICAL

Routine schedule immunisations will be given according to NHS guidelines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.

Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.

Intervention Type BIOLOGICAL

Routine schedule immunisations except monovalent MenC vaccine

Routine schedule immunisations will be given according to NHS guidelines.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female infants aged 6-12 weeks at the time of the first vaccination and who were born between 37 and 42 weeks of gestation
* Infants who are known to be free from medical problems as determined by a medical history and clinical examination
* Parents or guardians who are willing for their child to participate and who would be expected to comply with the requirements of the protocol
* Parents/guardians who have given informed consent for their child's participation in the study

Exclusion Criteria

* History of invasive meningococcal C disease
* Previous vaccination against meningococcal serogroup C disease
* Planned administration/administration of vaccines, since birth, other than the study vaccines (with the exception of oral rotavirus vaccine, Hepatitis B vaccine and BCG).
* Receipt of investigational vaccines/drugs, other than the vaccines used in the study, within 30 days prior to receiving the first dose of the vaccines or their planned use during the study period
* Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
* A family history of congenital or hereditary immunodeficiency.
* Receipt of more than 2 weeks of immunosuppressants or immune modifying drugs, (e.g. prednisolone \>0.5mg/kg/day)
* History of allergy to any component of the vaccines.
* Major congenital defects or serious chronic illness.
* History of any neurologic disorders or seizures
* Acute disease at the time of recruitment as defined by the presence of a moderate or severe illness with or without fever (with the exception of minor illnesses such as diarrhoea, mild upper respiratory infection without fever). In such situations enrolment should be postponed until the participant has recovered.
* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period
* Parents who plan to move out of the geographical area where the study would be conducted.

Minimum Eligible Age

2 Months

Maximum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes